SHIM
AZN icon

Stone House Investment Management’s AstraZeneca AZN Stock Holding History

Stone House Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.39K Buy
39
+1
+3% +$188 ﹤0.01% 484
2026
Q1 		$7.49K Sell
38
-1
-3% -$193 ﹤0.01% 396
2025
Q4 		$7.08K Buy
+39
New +$6.84K ﹤0.01% 366
2024
Q4 		– Sell
-23
Closed -$3.51K – 74
2024
Q3 		$3.51K Hold
23
– – ﹤0.01% 304
2024
Q2 		$3.51K Hold
23
– – ﹤0.01% 297
2024
Q1 		$3.05K Buy
+23
New +$3.05K ﹤0.01% 317

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stone House Investment Management's AZN Position: Q2 2026 in Review

Stone House Investment Management increased its AstraZeneca (AZN) stake by 2.6% in Q2 2026, buying an estimated $188 and bringing the position to 39 shares worth $7.39K. The position accounts for ﹤0.01% of the portfolio, ranked #484.

Stone House Investment Management first reported a position in AZN in Q1 2024 and has held it in 6 quarters since. The position peaked at $7.49K in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Stone House Investment Management held 39 shares of AstraZeneca worth $7.39K as of Q2 2026.
  • Stone House Investment Management bought 1 AstraZeneca share in Q2 2026, an estimated $188.
  • AstraZeneca made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #484 holding.
  • Stone House Investment Management first reported a position in AstraZeneca in Q1 2024 and has held it in 6 quarters since.
  • Stone House Investment Management's AstraZeneca position peaked at $7.49K in Q1 2026.
  • 1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.